Low-dose vemurafenib monotherapy in BRAFV600E -mutated Erdheim-Chester disease

Leuk Lymphoma. 2020 Nov;61(11):2733-2737. doi: 10.1080/10428194.2020.1783447. Epub 2020 Jul 1.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Erdheim-Chester Disease* / diagnosis
  • Erdheim-Chester Disease* / drug therapy
  • Erdheim-Chester Disease* / genetics
  • Humans
  • Indoles / adverse effects
  • Mutation
  • Proto-Oncogene Proteins B-raf* / genetics
  • Sulfonamides
  • Vemurafenib

Substances

  • Indoles
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf